{"entity":{"id":"nct06359275","kind":"trial","name":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","aka":[],"tldr":"A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Fudan University, now recruiting.","summary":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients is a phase 2, interventional study registered as NCT06359275 by Fudan University, with a registry enrolment figure of 81 participants, started 2024-06-01 and due to reach its primary completion in 2025-12. Interventions recorded: PD-1; Nab-paclitaxel; Gemcitabine; PULSAR. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-free survival (PFS). Pancreatic eligibility wording from the registry: \"Locally advanced pancreatic adenocarcinoma confirmed by histopathology or cytology, or pancreatic cancer with only local recurrence but no distant metastasis after surgery (local recurrence includes tumor bed recurrence and regional lymph node metastasis, which needs to be confirmed by biopsy pathol\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06359275","url":"https://clinicaltrials.gov/study/NCT06359275"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["nab-paclitaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06359275","phase":"2","setting":"A Phase II Study on the Safety and Efficacy of PD-1 Combined With Nab-paclitaxel/Gemcitabine and PULSAR in the Treatment of Locally Advanced Unresectable Pancreatic Cancer and Local Recurrence After Surgery.","sponsor":"Fudan University","enrolled":81,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06359275/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}